These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12621790)

  • 21. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol.
    Winkler UH; Ferguson H; Mulders JA
    Contraception; 2004 Jun; 69(6):469-76. PubMed ID: 15157791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism.
    Oner G; Muderris II
    Contraception; 2011 Nov; 84(5):508-11. PubMed ID: 22018126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
    Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
    Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative analysis of the effects of nomegestrol acetate/17 β-estradiol and drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea.
    Witjes H; Creinin MD; Sundström-Poromaa I; Martin Nguyen A; Korver T
    Eur J Contracept Reprod Health Care; 2015; 20(4):296-307. PubMed ID: 25712537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ethinyl estradiol 20μg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder.
    Marr J; Heinemann K; Kunz M; Rapkin A
    Int J Gynaecol Obstet; 2011 May; 113(2):103-7. PubMed ID: 21338987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective study on sexual behavior of women using 30 microg ethinylestradiol and 3 mg drospirenone oral contraceptive.
    Caruso S; Agnello C; Intelisano G; Farina M; Di Mari L; Sparacino L; Cianci A
    Contraception; 2005 Jul; 72(1):19-23. PubMed ID: 15964287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being.
    Mansour D
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():35-41; discussion 42-3. PubMed ID: 12659405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen.
    Marr J; Niknian M; Shulman LP; Lynen R
    Contraception; 2011 Jul; 84(1):81-6. PubMed ID: 21664515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms.
    Sangthawan M; Taneepanichskul S
    Contraception; 2005 Jan; 71(1):1-7. PubMed ID: 15639064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism.
    Batukan C; Muderris II
    Fertil Steril; 2006 Feb; 85(2):436-40. PubMed ID: 16595223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of low-dose combined drospirenone-ethinylestradiol on perimenstrual symptoms experienced by women with endometriosis.
    Tanaka Y; Mori T; Ito F; Koshiba A; Kusuki I; Kitawaki J
    Int J Gynaecol Obstet; 2016 Nov; 135(2):135-139. PubMed ID: 27477035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention.
    Fruzzetti F; Lazzarini V; Ricci C; Quirici B; Gambacciani M; Paoletti AM; Genazzani AR
    Contraception; 2007 Sep; 76(3):190-4. PubMed ID: 17707715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).
    Barbosa IC; Filho CI; Faggion D; Baracat EC
    Contraception; 2006 Jan; 73(1):30-3. PubMed ID: 16371291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study.
    Machado RB; de Melo NR; Maia H
    Contraception; 2010 Mar; 81(3):215-22. PubMed ID: 20159177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective study on the cytological aspects of the nasal respiratory epithelium in premenopausal women taking 30 mcg ethinylestradiol and 3 mg drospirenone oral contraceptive.
    Caruso S; Serra A; Grillo C; Agnello C; Di Mari L; Cianci A
    Contraception; 2008 May; 77(5):344-9. PubMed ID: 18402850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol.
    Paoletti AM; Lello S; Fratta S; Orrù M; Ranuzzi F; Sogliano C; Concas A; Biggio G; Melis GB
    Fertil Steril; 2004 Mar; 81(3):645-51. PubMed ID: 15037415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
    Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I
    Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives.
    Seeger JD; Loughlin J; Eng PM; Clifford CR; Cutone J; Walker AM
    Obstet Gynecol; 2007 Sep; 110(3):587-93. PubMed ID: 17766604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of a new oral contraceptive containing drospirenone.
    Shulman LP
    J Reprod Med; 2002 Nov; 47(11 Suppl):981-4. PubMed ID: 12497672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome.
    De Leo V; Morgante G; Piomboni P; Musacchio MC; Petraglia F; Cianci A
    Fertil Steril; 2007 Jul; 88(1):113-7. PubMed ID: 17418832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.